摘要
目的对比顽固性心力衰竭患者应用沙库巴曲缬沙坦与缬沙坦治疗的疗效与安全性。方法抽取我院顽固性心力衰竭患者68例作为研究对象,以随机数字表法分为观察组和对照组,各34例。2组均接受常规治疗,在此基础上观察组给予沙库巴曲缬沙坦,对照组给予缬沙坦,对比2组的疗效、安全性以及心脏超声指标。结果治疗后,观察组LVEDd、hs-c Tn T、NT-pro BNP显著低于对照组、LVEF显著高于对照组(P<0.05);对照组患者总有效率为76.47%(26/34),观察组为94.12%(32/34),差异有统计学意义(P<0.05);观察组不良反应发生率为5.88%(2/34),对照组为11.76%(4/34),差异无统计学意义(P>0.05)。结论与缬沙坦相比较,顽固性心力衰竭患者应用沙库巴曲缬沙坦治疗的疗效更为显著,安全性良好。
Objective To investigate the safety and efficacy of shakubarb valsartan and valsartan in the treatment of refractory heart failure.Methods 68 patients with refractory heart failure in our hospital were selected as experimental objects and divided into observation and control groups with 34 cases in each group by random digital sampling table method.Both groups received long-term conventional treatment.On this basis,patients in the observation group were treated with shakubarb valsartan,while patients in the control group were treated with valsartan.The efficacy,safety and cardiac ultrasound data of the two groups were observed and compared.Results After treatment,LVEDD,hs-cTnT,and NT-pro BNP in the observation group were significantly lower than those in the control group,and LVEF was significantly higher than that in the control group.The effective rate of patients in the control group was 76.47%(26/34)and that in the observation group was 94.12%(32/34),with statistically significant difference(P<0.05).The incidence of adverse reactions was 5.88%(2/34)in the observation group and 11.76%(4/34)in the control group,with no significant difference(P>0.05).Conclusion Compared with valsartan,the treatment of patients with refractory heart failure with shakubarb valsartan is more effective and safe.
作者
董德怀
程海生
Dong Dehuai;Cheng Haisheng(The Traditional Chinese Medicine Hospital of Maoming City,Maoming,Guangdong 525000)
出处
《基层医学论坛》
2020年第17期2381-2383,共3页
The Medical Forum
作者简介
董德怀,男,本科,主治医师。
